Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors (GIST), according to research presented at the European Society for Medical Oncology (ESMO) Congress 2023.
Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors (GIST), according to research presented at the European Society for Medical Oncology (ESMO) Congress 2023.
